Fermented Dairy Product and Bifidobacterium Diversity
A Randomised, Controlled, Double-blind, Parallel Groups, Single-centre Study to Assess the Bifidobacterium Diversity After 28-days Consumption of a Fermented Dairy Product With Three Bifidobacterium Strains Compared to Yoghurt in 45 to 60-year-old Healthy Subjects
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Danone Global Research & Innovation Center
- Telefoonnummer: +33 (0)1 69 35 70 00
- E-mail: register.clinicalresearchnutricia@danone.com
Studie Locaties
-
-
-
Dijon, Frankrijk
- Werving
- CEN
-
Hoofdonderzoeker:
- Carole PERRIN, Dr
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Male and female subjects aged between 45 and 60 years old.
- BMI between 18.5 kg/m² and 30 kg/m².
- Subjects who are overtly healthy as determined by the investigator.
- Able to speak and read in French.
- Willing and able to collect their faecal samples themselves.
- Having access to adequate space to store the investigational.
- Regular bowel movements.
- Willing to consume the study products twice per day for 28 consecutive days.
- Willing not to consume any fermented dairy products during the entire study, other than the study products.
- Willing not to consume any probiotic, prebiotic or synbiotic supplements during the entire study.
- Willing to limit alcohol consumption during the study.
- Willing not to smoke tobacco during the study.
- Willing not to use any soft or hard drug during the study.
- Signed written informed consent by the participant.
- Female subjects must either be postmenopausal for at least 12 months or have undergone specific surgical procedures resulting in sterility or they are using one of the medically approved contraceptive methods.
- Subject is covered by French health insurance.
- Subject agrees to be registered in the national database of subjects participating in clinical research.
- Subject is willing and able to complete the electronic Patient Reported Outcomes using their own digital device having access to internet.
Exclusion Criteria:
- Any ongoing metabolic disease, hypertension, inflammatory disease, thyroid disease, allergic conditions requiring chronic systemic medication, psychiatric disorder, gastrointestinal disorder, chronic pain, or neurological disorder diagnosed by a physician.
- Known with allergy or intolerance to any ingredients or allergens.
- Pregnancy or breast-feeding at the screening visit or plan for pregnancy during the study.
- Any antecedents of digestive surgery, or plan for such surgery during the study.
- Any dental surgery within the last 4 weeks before the screening visit, or plan for dental surgery during the study.
- Subject who had any surgery or intervention requiring a general anaesthesia in the preceding 4 weeks before the screening visit, or who plans to have one during the study.
- Unable (or unwilling) to adhere to protocol requirements.
- Subject with a special diet at the screening visit, or plan for such diet during the study.
- Major changes in subject's dietary habits ≤ 4 weeks before the screening visit or plan for such major changes during the study including change in vitamin or mineral supplements use, but except for dietary restrictions related to the study.
- Enhanced diet together with intense physical activity ≤ 4 weeks before the screening visit, plan for such a diet and training during the study, or plan for major changes in physical activity during the study.
- Use ≤ 8 weeks before the screening visit or plan of use during the study of systemic medication that can affect the gastrointestinal function or plan of use during the study (if needed, incidental use of ≤ 4 tablets of paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin per 2-week period is allowed.
- Excessive alcohol consumption during the past 6 months before the screening visit.
- Active smoker, or quit active smoking less than 5 years ago before the screening visit. Not regularly smoking is allowed.
- Drug abuse based on investigator's judgement.
- Participation in another study with investigational or marketed products potentially affecting the gut microbiota ≤ 4 weeks before the screening visit or plan for participation in any other intervention study during the study.
- Living in the same home as others already participating in the study and to concomitantly receive some study products.
- Subject under guardianship, curatorship, person under judicial protection, family empowerment or future protection mandate.
- Employees, family members or other relatives of employees of the participating centre or of Danone Global Research & Innovation Center.
- Subject's total compensation for participation in clinical studies within the past 12 months, including the compensation expected from the Mellifera study, would exceed the annual ceiling of €6,000.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Orale toediening van experimenteel product a
Testproduct A: Gefermenteerd zuivelproduct dat Bifidobacterium -stammen bevat
|
40 healthy volunteers will consume Product A twice per day during 28 consecutive days
|
|
Placebo-vergelijker: Oral administration of Control product
Control product: commercially available yoghurt without Bifidobacterium strains
|
40 healthy volunteers will consume Control product twice per day during 28 consecutive days
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
De primaire uitkomstparameter in deze studie is de verandering ten opzichte van de basislijn na 28 dagen productverbruik van het aantal verschillende bifidobacteriumsoorten.
Tijdsspanne: Na 28 dagen bestudeerproductverbruik
|
Na 28 dagen bestudeerproductverbruik
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
De verandering ten opzichte van de basislijn na 28 dagen productverbruik van Bifidobacterium diversiteitsindices.
Tijdsspanne: Na 28 dagen bestudeerproductverbruik
|
Na 28 dagen bestudeerproductverbruik
|
|
The proportion of subjects with presence of viable bacteria of the provided Bifidobacterium strains after 28-days product consumption.
Tijdsspanne: After 28 days of study product consumption
|
After 28 days of study product consumption
|
|
The changes from baseline after 28-days product consumption in quantification of viable bacteria of the provided Bifidobacterium strains.
Tijdsspanne: After 28 days of study product consumption
|
After 28 days of study product consumption
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- 26REX0099946
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .